Has Sibi Ipe received payments from drug or device companies?

Yes. Drug and device makers reported $2,032 in general payments to Sibi Ipe across 69 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sibi Ipe did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sibi Ipe come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sibi Ipe

Physician Assistant · Allen, TXNPI 1366607301

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,380 of the $2,032 with a category attached, or 67.9%. 26 manufacturers reported payments, led by Astellas Pharma US Inc at 30.4% of the total. Reporting peaked in 2022 at $1,013 and has fallen 78.5% since, to $218 in 2025.

$2,032in general payments, 2019–2025

Across 69 payments — averaging $29.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astellas Pharma US Inc$618
Incyte Corporation$468
Merck$150
Sanofi$68
Jazz Pharmaceuticals Inc.$67
ADC Therapeutics America, Inc.$63
plus $598 from 20 others

What the payments were for

Food & beverage$1,38068%
Education$65232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astellas Pharma US Inc	10	$618
Incyte Corporation	17	$468
Merck	6	$150
Sanofi	2	$68
Jazz Pharmaceuticals Inc.	3	$67
ADC Therapeutics America, Inc.	3	$63
Blueprint Medicines Corporation	3	$62
Rigel Pharmaceuticals, Inc.	3	$51
Servier Pharmaceuticals LLC	2	$44
Takeda Pharmaceuticals U.S.A., Inc.	2	$42
Syndax Pharmaceuticals, Inc.	2	$42
GSK	2	$37
Johnson & Johnson	1	$32
Sobi, Inc	1	$32
Regeneron Healthcare Solutions, Inc.	1	$30
Adaptive Biotechnologies Corporation	1	$30
Geron Corporation	1	$25
Janssen Scientific Affairs, LLC	1	$24
Dova Pharmaceuticals	1	$23
Karyopharm Therapeutics Inc.	1	$20
Legend Biotech USA Inc.	1	$20
Menarini Silicon Biosystems, Inc.	1	$19
Mirati Therapeutics, Inc.	1	$18
Acrotech Biopharma Inc.	1	$17
Genmab U.S., Inc.	1	$15
CTI Biopharma Corp.	1	$14

How this compares

$2,032 in reported general payments places this provider in the 75th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ValacyclovirValacyclovir Hcl	26	$929
Levofloxacin	11	$129
Acyclovir	22	$120

Paid to pharmacies, not to this prescriber.

Other physician assistant in Allen

Cynthia TrickettDallas$1.3M
Kristine KuceraMelissa$797K
Selina SantosAustin$543K
Matthew BrunoMcKinney$538K
Brooke HodnickSouthlake$479K
Holly GloverArlington$418K
Kirk GautierAthens$416K
Jaime RomanPlano$338K
Michael WhiteDallas$276K
Heidi JeffreysLubbock$259K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →